Compare DexCom, Inc. (DXCM) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs KeyCorp — how do they compare? DexCom, Inc. trades at $83.88 (market cap $31.86B), while KeyCorp trades at $19.95 (market cap $21.45B). The key difference: DexCom, Inc. is the larger of the two by market cap, and KeyCorp pays a 4.08% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and KeyCorp for 66 Days on average.
| DXCM | KEY | |
|---|---|---|
Market Cap | $31.86B | $21.45B |
Volume | 3,607,070 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $92.34 | $23.99 |
52-Week Low | $54.84 | $16.78 |
Typical Hold Time | 62 Days | 66 Days |
Enterprise Value | $31.32B | $34.63B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
KeyCorp (KEY) trades at $19.83, down 1.54% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent management appointments and a 2026 revenue outlook raise to 8% growth signal operational momentum. However, technical indicators show oversold conditions with RSI at 26.31 and bearish moving average signals.
KEY presents a value opportunity with attractive valuation metrics and consistent earnings performance. The 26% upside to consensus price target of $25.00 and 60.79% analyst buy rating support bullish sentiment. Risks include frozen dividend payments since 2023 and sensitivity to interest rate changes. The bank's aggressive share buyback program and improving net interest income provide catalysts for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
